Successful Crackdown on Illegal Use of Methylphenidate

Regulations by 2FIRSTS.ai
Nov.20.2023
Successful Crackdown on Illegal Use of Methylphenidate
Seven suspects were arrested in Ganzhou, Jiangxi for illegal use of illicit substance meprobamate in e-cigarette manufacturing.

According to the news on November 20th from Guizhou Internet Radio and Television Station, the Xinfeng police in Ganzhou, Jiangxi recently successfully cracked a case involving the use of methyl ethyl ketone to produce "Shangtou e-cigarettes". In total, seven suspects involved in illegal activities were arrested.

Successful Crackdown on Illegal Use of Methylphenidate

 

According to data from the police, the urine test results of arrested suspects have all shown positive for eutylone. On the other hand, cases related to eutylone have also been successively cracked in Xishui, Hubei and Yuncheng, Guangdong, once again highlighting the dangers of eutylone in the illegal market.

 

Dependence on Etomidate", known as a type of prescription anesthetic, can only be legally used by medical institutions that have obtained a "Pharmaceutical Business License." Similarly, only pharmaceutical wholesale and retail enterprises with a "Pharmaceutical Business License" can sell raw materials and preparations of "Etomidate.

 

In September of this year, the National Medical Products Administration, Ministry of Public Security, and National Health Commission issued a public announcement regarding the adjustment of the catalogue of anesthetic and psychotropic drugs. It states that methylphenidate will be included in the second category of the psychotropic drug catalogue, excluding drugs containing methylphenidate that have been approved for sale within China. This adjustment will take effect from October 1, 2023.

 

Disclaimer: 
This article is translated from an original Chinese article available on 2firsts.cn by AI, and has been reviewed and edited by 2FIRSTS's English editorial team. The Chinese original text is the only authoritative source of information. The exclusive copyright and license rights to this article are held by 2FIRSTS Technology Co., Ltd. Any reproduction, reprinting, or redistribution of this article, either in part or in full, requires express written permission from 2FIRSTS and must include clear attribution along with a link to this content. Non-compliance may result in legal action. 2FIRSTS Technology Co., Ltd. reserves the right to pursue legal actions in case of unauthorized use or distribution.